[
  {
    "article_id": 121,
    "article_title": "Pediatric Cardiology",
    "section_id": "01416fb2a0d04770ac92806830141765",
    "section_title": "Clinical Assessment and Management",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Initial Evaluation**\n\nEvaluation begins with a focused history addressing the presenting complaint, family history of cardiac disease, and functional capacity. Systematic physical examination is performed, including vital signs with age-appropriate blood pressure measurement, cardiac auscultation for murmurs and abnormal sounds, and assessment for signs of heart failure such as hepatomegaly or peripheral edema.\n\n**Diagnostic Testing**\n\nElectrocardiography is interpreted using age-specific normal standards for infants and children. Imaging is selected based on clinical suspicion: echocardiography for initial structural assessment, cardiac MRI or CT for detailed anatomical definition when needed, and chest radiography to evaluate cardiac silhouette and pulmonary vascularity.\n\n**Chest Pain Evaluation**\n\nMost pediatric chest pain referrals represent low-probability cardiac cases. Detailed characterization of pain quality, duration, triggers, and associated symptoms is obtained. Thorough physical examination and electrocardiography are performed. Reassurance and explanation of benign findings often suffice; cardiac imaging is reserved for cases with clinical features suggesting organic disease.\n\n**Blood Pressure Management**\n\nBlood pressure is measured using an appropriately sized cuff with the child seated and at rest. Readings are compared to age, sex, and height-specific reference standards. Elevated readings warrant confirmation on repeat visits before pharmacological intervention is initiated.\n\n**Murmur Assessment**\n\nMurmurs are characterized by timing (systolic, diastolic, continuous), location, radiation, quality, and intensity. Findings are correlated with clinical context, including growth and development, exercise tolerance, and associated symptoms. Innocent murmurs typically have characteristic features that distinguish them from pathological lesions; echocardiography confirms the diagnosis when clinical uncertainty exists."
  },
  {
    "article_id": 122,
    "article_title": "Immunodeficiency",
    "section_id": "0575f9ca53894d25807ca63ec2153bcb",
    "section_title": "Clinical Evaluation and Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Initial Assessment**\n\nPrimary immunodeficiency is suspected in children presenting with:\n- Recurrent infections requiring intravenous antibiotics\n- Recurrent deep-seated infections\n- Chronic oral or cutaneous candidiasis\n- Chronic diarrhoea with atypical features\n- Complications from live vaccines\n- Autoimmune disease or malignancy\n\n**Diagnostic Workup**\n\n1. A detailed infection history is obtained (frequency, severity, type, response to treatment)\n2. Serum immunoglobulin levels (IgG, IgA, IgM) are measured\n3. Specific antibody responses are assessed\n4. B and T cell enumeration and functional studies are performed\n5. Molecular genetic testing is considered based on clinical phenotype\n6. Referral to an immunologist is made for diagnosis confirmation and assessment of the degree of immunodeficiency\n\n**Immunisation Strategy**\n\nVaccine approach depends on immunodeficiency category:\n\n- **Selective IgA deficiency**: All live-virus and inactivated vaccines are given as per standard schedule\n- **Major antibody deficiencies or SCID on immunoglobulin therapy**: Routine inactivated vaccines are avoided (except inactivated [[298|influenza]] vaccine); inactivated vaccines may be given as part of pre-therapy immunologic assessment\n- **Common variable immunodeficiency**: Annual inactivated influenza vaccine is given; meningococcal conjugate vaccine (MenACWY) is begun at 2 months of age due to splenic dysfunction and inadequate meningococcal antibody coverage in immunoglobulin replacement\n\n**Ongoing Management**\n\nCare is coordinated with an immunologist for:\n- Immunoglobulin replacement therapy decisions\n- Monitoring for complications (malignancy, autoimmunity, progressive organ involvement)\n- Gastrointestinal surveillance in conditions with known GI manifestations\n- Genetic counselling for family members"
  },
  {
    "article_id": 125,
    "article_title": "Pertussis",
    "section_id": "4436fdd5fc1140a9a4a3797ed995aca7",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Diagnosis and initial assessment**\n\n- Nasopharyngeal secretions are obtained for PCR or culture to confirm diagnosis\n- Complete blood count is performed; leukocytosis with absolute lymphocytosis is expected (though this may be absent in infants)\n- Chest radiograph is obtained; obliteration of cardiac borders or signs of [[150|pneumonia]] and atelectasis are sought\n- In infants, the characteristic inspiratory whoop may be absent and classic laboratory findings may not be present\n\n**Clinical evaluation**\n\n- Paroxysmal cough pattern and posttussive vomiting are assessed\n- [[151|Respiratory distress]], cyanosis, apnea, bradycardia, and poor feeding are monitored for in infants\n- Complications including [[150|pneumonia]], [[315|seizures]], and signs of secondary [[278|bacterial infection]] are evaluated\n- [[226|Sepsis]] in infants is distinguished by the paroxysmal cough pattern on examination\n- Auscultation of the chest is usually normal despite severe cough\n\n**Infection control**\n\n- Pertussis is highly communicable during the catarrhal and early paroxysmal cough stages (approximately 4 weeks after onset)\n- Appropriate respiratory isolation precautions are implemented"
  },
  {
    "article_id": 126,
    "article_title": "Ventricular Septal Defect",
    "section_id": "b7ba637741464906b0ae2be4f15ca09b",
    "section_title": "Clinical Assessment and Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Initial Evaluation**\n\nThe infant is assessed for signs of heart failure: failure to thrive, tachypnea, diaphoresis during feeding, hepatomegaly, and poor feeding tolerance. These symptoms typically emerge at 3–6 months of age in infants with large defects.\n\nCardiac auscultation identifies a pansystolic murmur (which masks the first heart sound), and a thrill is palpated for. Small defects may produce no murmur.\n\n**Diagnostic Confirmation**\n\nEchocardiography is the primary diagnostic modality. Apical four-chamber views are used for perimembranous defects and short-axis views for muscular defects. Color flow Doppler interrogation is performed, particularly for small muscular defects in the apical region.\n\nA chest radiograph is obtained to assess for cardiomegaly, left atrial enlargement, and increased pulmonary artery flow.\n\n**Management Strategy**\n\n**Small defects** (< 3 mm): Clinical observation is appropriate. No intervention is required in most cases, as spontaneous closure occurs in the majority. Follow-up echocardiography can be performed to document closure.\n\n**Large defects** (6–10 mm) with normal pulmonary vascular resistance and symptoms of heart failure: Surgical evaluation is warranted. Surgery is performed before age 2 years to prevent the development of pulmonary vascular obstructive disease.\n\n**Timing of intervention** depends on the clinical situation. Infants with symptoms of failure to thrive, significant tachypnea, and poor feeding at 3–6 months of age require correction at that time."
  },
  {
    "article_id": 128,
    "article_title": "Ankle Sprain",
    "section_id": "751dd986b8714b819ed43c083c835323",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Initial Assessment**\n\n1. Point tenderness over the anterior talofibular ligament and calcaneofibular ligament is examined for\n2. Passive inversion is tested—marked pain indicates ligament injury\n3. Weight-bearing ability is assessed; most children can bear slight weight\n4. X-rays are obtained in skeletally immature athletes to exclude fracture\n\n**Acute Phase (First 48–72 Hours)**\n\n- **Protection and immobilization**: An air splint, elastic wrap, or ankle stirrup brace is applied to support the ankle in a functional position (right angle)\n- **Rest**: Ambulation or exercise is allowed only if it causes no pain or swelling during activity or within 24 hours. Crutches and light weight-bearing are used if pain occurs\n- **Ice**: Applied directly to the ankle for 20 minutes every 2 hours for the first 48 hours\n- **Compression**: Elastic wrap or air splint provides compression\n- **Elevation**: The extremity is elevated to reduce swelling\n- **NSAIDs**: Included as part of the treatment regimen\n\n**Rehabilitation**\n\n- Functional rehabilitation begins as soon as possible\n- Focus is on edema control, range of motion, strengthening, and proprioceptive restoration\n- Weight-bearing progresses as tolerated\n- Formal physical therapy is arranged\n- A lace-up ankle brace is prescribed for ongoing support and prevention of recurrence"
  },
  {
    "article_id": 129,
    "article_title": "Dysfunctional Uterine Bleeding",
    "section_id": "8894e114f3d34b4fbe04ac947cc8f886",
    "section_title": "Etiology and Pathophysiology",
    "variant": "long",
    "imperatives": 1,
    "content": "The most common cause of AUB in adolescents is anovulation secondary to immaturity of the hypothalamic-pituitary-ovarian axis, particularly during the first 1–2 years after menarche. However, AUB is a diagnosis of exclusion, and other causes must be investigated.\n\nOther potential causes include:\n\n- Thyroid dysfunction and hyperprolactinemia\n- Hypothalamic dysfunction related to exercise, stress, or changes in body weight\n- Bleeding disorders (including inherited coagulation defects)\n- Vaginal lacerations, hymenal tears, or foreign bodies\n- Sexually transmitted infections causing intermenstrual bleeding\n- Use of hormonal contraceptives or intrauterine devices\n- Vaginal adenocarcinoma (in girls whose mothers received diethylstilbestrol)\n- Psychosocial factors such as trauma or stress"
  },
  {
    "article_id": 129,
    "article_title": "Dysfunctional Uterine Bleeding",
    "section_id": "ceabf317c34d4f68bc36d6a6fe0feabb",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 4,
    "content": "**Initial Assessment**\n\n1. A detailed menstrual history is obtained: age at menarche, cycle length, duration of flow, volume of bleeding, and pattern of bleeding\n2. Bleeding risk is screened for: history of easy bruising, nosebleeds, family history of bleeding disorders, and heavy bleeding in relatives\n3. Complete physical examination is performed, including vital signs, assessment for pallor or signs of [[349|anemia]], thyroid palpation, and pelvic examination as appropriate\n4. Hemoglobin or hematocrit is measured\n\n**Stratification and Management**\n\n| Clinical Scenario | Management |\n|---|---|\n| Mild bleeding, normal hemoglobin, no contraceptive need | Observation and reassurance |\n| Low hemoglobin level (with or without other signs of iron deficiency) | Iron supplementation |\n| Symptomatic anemia or actively bleeding | Hospitalization |\n\n**Pharmacologic Options**\n\n- **Nonsteroidal anti-inflammatory drugs**: Ibuprofen or naproxen are used to reduce menstrual flow\n- **Combined hormonal contraceptives**: Highly effective for reducing or eliminating abnormal bleeding when appropriate for the adolescent\n\n**Further Investigation**\n\nBased on clinical findings, further testing may include:\n\n- Thyroid function tests if thyroid dysfunction is suspected\n- Coagulation studies if there is a personal or family history of bleeding disorder\n- Testing for sexually transmitted infections if intermenstrual bleeding or risk factors are present\n- Pelvic ultrasound if structural pathology is suspected"
  },
  {
    "article_id": 132,
    "article_title": "Type 1 Diabetes Mellitus",
    "section_id": "2d08c10839074e0181f53b06ca4a077e",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Initial Assessment and Diagnosis**\n\nDiagnosis is confirmed using American Diabetes Association criteria:\n- Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), OR\n- 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during 75-g oral glucose tolerance test, OR\n- Random plasma glucose ≥200 mg/dL (11.1 mmol/L) with classic hyperglycemia symptoms, OR\n- HbA1C ≥6.5%\n\nFasting or stimulated C-peptide is measured to assess remaining beta cell function. Autoantibodies (islet cell antibodies, anti-GAD, IA-2, insulin autoantibodies) are screened for to confirm autoimmune etiology.\n\n**Ongoing Management**\n\nAn intensive insulin regimen is implemented with the following components:\n\n1. **Insulin dosing and timing**: Children receiving fixed-dose insulin eat at consistent times coinciding with the peak action of the insulin preparation used. Insulin doses are adjusted based on food intake, physical activity, and blood glucose concentrations.\n\n2. **Flexible regimens**: Children using insulin pumps or basal-bolus regimens with long-acting basal insulin preparations (glargine, detemir) have flexibility in meal timing due to absence of significant peaks in basal insulins.\n\n3. **Dietary management**: A balanced diet with carbohydrate counting matched to insulin administration is provided.\n\n4. **Exercise**: Regular physical activity is encouraged as part of the management plan.\n\n5. **Blood glucose monitoring**: Essential monitoring is performed to maintain near-normal glycemia.\n\n6. **Target glycemic control**: HbA1c is maintained at <48 mmol/mol (6.5%) to reduce long-term complications.\n\n**Patient and Family Education**\n\nAdjustment of all diabetes regimen components (insulin, diet, exercise, monitoring) is taught. A united team approach with unambiguous guidelines is established. Progress is communicated promptly, and peer group support is used to promote adherence and health outcomes."
  },
  {
    "article_id": 133,
    "article_title": "Acute Asthma Exacerbation",
    "section_id": "2009346a94ce40b1a0f1ad1c5ecdfcc1",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Immediate Assessment**\n\nSeverity is rapidly evaluated using clinical signs:\n- Accessory muscle use, limited ability to speak, upright posture preference\n- Paradoxical pulse >25 mm Hg\n- Heart rate >130 bpm, respiratory rate >25 breaths/min\n- Peak expiratory flow <50% predicted\n- Oxygen saturation <92%\n- Any sign of life-threatening exacerbation (silent chest, drowsiness, confusion)\n\n**If any severe or life-threatening signs are present, immediate transfer to the ED is required**\n\n---\n\n**First-Line Therapy**\n\n1. **Supplemental oxygen** — administered as first-line therapy to maintain adequate oxygenation; close monitoring for deterioration is essential\n\n2. **Short-acting beta-agonist (SABA)** — frequent bronchodilator treatments are given\n   - Home treatment: 2–4 puffs via metered dose inhaler, or 1–2 puffs SABA in combination treatment\n\n3. **Systemic corticosteroids** — a course of oral or intravenous corticosteroid is given\n   - IV corticosteroids are considered if the patient is unable to tolerate the oral route\n\n---\n\n**Additional Considerations**\n\n- **High-dose ipratropium bromide** — addition leads to decreased rate of hospitalization\n- **Intravenous magnesium** — considered in severe exacerbations\n- **Caution with SABA dosing**: increasing frequency and dosage increases pulmonary blood flow through obstructed, poorly oxygenated areas, worsening ventilation/perfusion mismatch and hypoxemia if airway obstruction is not resolved\n\n---\n\n**Follow-Up After ED or Hospitalization**\n\n- Outpatient follow-up within 1–2 days in children\n- Outpatient follow-up within 1 week in adolescents\n- A written [[107|asthma]] action plan is ensured to be in place before discharge"
  },
  {
    "article_id": 134,
    "article_title": "Birth Asphyxia",
    "section_id": "f55c4ae0d169470ea61f9925579c5ab9",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 5,
    "content": "**Initial Assessment and Approach**\n\nWhen an infant does not breathe at birth, secondary apnea is assumed to be present and resuscitation is begun immediately. Primary and secondary apnea are not distinguished clinically.\n\n**Immediate Actions**\n\n1. **The infant's condition is assessed** using the Apgar score at 1 minute and 5 minutes after delivery, and at 5-minute intervals if the infant remains unwell. Heart rate, respiratory effort, muscle tone, reflex irritability, and colour are evaluated.\n\n2. **Tactile stimulation is provided** (drying, slapping the feet) as an initial measure; this may restart breathing in primary apnea but is not effective in secondary apnea.\n\n3. **Ventilatory support is initiated** without delay if the infant remains apnoeic or has inadequate respiratory effort after brief tactile stimulation. Ventilatory support must be provided within minutes to prevent death.\n\n**Ongoing Management**\n\nResuscitative efforts continue according to current American Heart Association and American Academy of Pediatrics guidelines. Heart rate, blood pressure, and oxygenation status are monitored. Signs of neonatal neurologic dysfunction (seizures, encephalopathy, abnormal tone) and multiple organ involvement (renal, pulmonary, hepatic, cardiac, gastrointestinal dysfunction) are assessed for.\n\nNote: The reference passages do not provide specific drug doses, ventilation parameters, or detailed resuscitation protocols. Current AHA-AAP resuscitation guidelines provide complete management algorithms."
  },
  {
    "article_id": 135,
    "article_title": "Child Sexual Abuse",
    "section_id": "c534b7d5c13c45d78fb2c804b6259429",
    "section_title": "Clinical Evaluation and Management",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Initial Assessment**\n\nA complete history and physical examination are performed. A high index of suspicion is maintained based on nonverbal clues, psychosomatic symptoms, and presenting complaints such as vaginal itching or discharge.\n\n**Physical Examination Technique**\n\nA systematic examination is conducted, including:\n- Inspection of genital, perianal, and anal areas using appropriate terminology\n- Assessment for anal and perianal abnormalities\n- Evaluation for evidence of sexually transmitted infections\n- Identification of foreign bodies\n- Documentation of nongenital injuries\n- Careful distinction between normal anatomical variants and signs of abuse\n- Assessment for internal injury when indicated\n\n**Interview Process**\n\n- The child is interviewed separately from parents, using age-appropriate techniques\n- Repetition of questioning is minimized to reduce trauma\n- Drawings are used as communication aids if helpful\n- Parents are interviewed separately\n- All information is documented carefully\n\n**Documentation and Reporting**\n\n- A legal chain of evidence is maintained throughout evaluation\n- Precise, objective documentation with appropriate anatomical terminology is used\n- A mandatory report to Child Protective Services is made if reasonable suspicion of abuse exists\n- Reporting occurs regardless of whether abuse can be definitively proven\n- This obligation applies in all 50 states"
  },
  {
    "article_id": 136,
    "article_title": "Congenital Adrenal Hyperplasia",
    "section_id": "dc748e7bac0f48fba239a978070b4567",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Recognition and Initial Assessment**\n\nCAH is suspected in any infant presenting with:\n- Ambiguous genitalia in a 46,XX infant\n- Salt-wasting crisis in a male infant aged 5–14 days: vomiting, weight loss, lethargy, poor feeding, [[99|dehydration]], tachycardia, or hypothermia\n- Abnormal newborn screening result (elevated 17-hydroxyprogesterone)\n\n**Immediate Investigations**\n\nUrgent blood tests are obtained:\n- Electrolytes (looking for [[170|hyponatremia]] and hyperkalemia)\n- Glucose\n- Venous or arterial blood gas (to assess for [[387|metabolic acidosis]])\n- 17-hydroxyprogesterone, renin, cortisol, and aldosterone levels\n- ECG is performed to assess for peaked T waves or arrhythmias from hyperkalemia\n\n**Acute Management of Salt-Wasting Crisis**\n\n1. **Fluid resuscitation:** Intravenous normal saline is administered to correct [[161|severe dehydration]] and [[170|hyponatremia]]\n2. **Glucocorticoid replacement:** Initiated immediately\n3. **Mineralocorticoid replacement:** Required in salt-wasting forms\n4. **Electrolyte monitoring:** Electrolytes are rechecked frequently during the acute phase\n5. **Cardiac monitoring:** Arrhythmias related to hyperkalemia are watched for\n\n**Ongoing Glucocorticoid Dosing**\n\n- Classic CAH (salt-wasting and simple virilizing forms): 10–15 mg/m²/day\n- Nonclassical CAH: 6–10 mg/m²/day\n\n**Specialist Referral**\n\nUrgent referral to a pediatric endocrinologist is arranged. Management involves a multidisciplinary team including endocrinology, genetics, urology, and psychosocial support, particularly for discussion of sex assignment and long-term management in virilized females."
  },
  {
    "article_id": 137,
    "article_title": "Dysmenorrhea",
    "section_id": "2cd0e14adecf4be3b229a06fdb0affef",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Initial Assessment**\n\n1. A complete menstrual history is taken, including timing of pain, duration and severity\n2. HEEADSSS psychosocial screening and detailed sexual history are performed\n3. Hidden agendas are explored (school avoidance, abuse history, secret sexual activity)\n4. Abdominal and pelvic examination is performed (per vaginum in sexually active adolescents)\n5. Red flags for secondary dysmenorrhea are identified: pain at menarche, intercycle pain, dyspareunia, abnormal discharge, pelvic mass or tenderness\n\n**First-Line Treatment: NSAIDs**\n\nTreatment is started as soon as the patient anticipates menstruation will begin:\n- **Naproxen**: twice daily (age and weight-appropriate dose)\n- **Ibuprofen**: every 6–8 hours (age and weight-appropriate dose)\n\nTreatment continues on schedule throughout menstruation. Reassessment occurs after 2–3 menstrual cycles.\n\n**Second-Line Treatment: Hormonal Suppression**\n\nFor patients not responding to NSAIDs:\n- **Oral contraceptive pills (OCPs)**: used as for contraception. The patient is informed that 2–3 cycles may elapse before maximal effect\n- **Levonorgestrel-releasing intrauterine device (LNG-IUD)**: effective for both primary and secondary dysmenorrhea\n- **Subdermal implant**: effective for both primary and secondary dysmenorrhea\n\nFor non-sexually active teenagers on OCPs, therapy is reassessed at 6–12 month intervals.\n\n**Investigation for Secondary Causes**\n\nIf pain persists despite appropriate NSAIDs and hormonal management for 6 months, or if red flags are present:\n- Pelvic ultrasound is arranged\n- Pelvic MRI is considered\n- Endometriosis is specifically screened for (most common secondary cause)\n- Müllerian anomalies, obstructive reproductive tract anomalies, myomas and ovarian cysts are evaluated for\n\n**Note**: Acetaminophen-containing products are not recommended as they are less effective than NSAIDs for dysmenorrhea."
  },
  {
    "article_id": 138,
    "article_title": "Feeding Difficulty",
    "section_id": "4106c4c85fa747459095f671d9a4aec8",
    "section_title": "Clinical Approach",
    "variant": "clinical",
    "imperatives": 4,
    "content": "**Initial Assessment**\n\n1. **History and observation**: A complete feeding session is observed. Feeding duration, volumes consumed, fatigue, respiratory symptoms, and vomiting or gagging are documented. Feeding schedule consistency, mealtime environment, and caregiver concerns are asked about.\n\n2. **Physical examination**: Neurologic signs, craniofacial abnormalities, oral anatomy (lip closure, tongue position, ankyloglossia), and signs of aspiration (recurrent respiratory infections, chronic lung disease) are assessed. The growth chart is examined for recent decline or weight below 5th centile.\n\n3. **Determine organic versus nonorganic etiology**: This distinction guides further workup. Organic causes (neurologic impairment, cardiac disease, pulmonary disease, anatomic abnormality) require specific investigation. Nonorganic causes (schedule inconsistency, environmental factors, caregiver practices) require behavioral and environmental intervention.\n\n**Diagnostic Considerations**\n\n- **Swallowing assessment**: If concerns exist regarding pharyngeal phase physiology or aspiration risk, instrumental assessment of swallowing is considered.\n- **Specific conditions**: [[171|Hypothyroidism]] is diagnosed through blood sample (low T3 and T4, high TSH). Prader-Willi syndrome presents with hypotonia in an otherwise normal child.\n- **Referral for specialist evaluation**: Occupational therapy or speech-language pathology is considered for assessment of oral-motor difficulties and aspiration risk, particularly in preterm infants or those with [[82|developmental delay]].\n\n**Management Principles**\n\n- **Correctable organic causes are addressed first**: Underlying conditions are treated (e.g., [[245|gastroesophageal reflux]], cardiac disease, [[171|hypothyroidism]]).\n- **Environmental optimization**: A consistent feeding schedule is established. The child is positioned in a high chair when available. Distractions (television) are removed. Ineffective positioning such as the hammerlock hold in the parent's lap is avoided.\n- **Feeding therapy**: Ongoing therapy for oral-motor difficulties may be required. Feeding evaluation and therapy may benefit infants with difficulty transitioning to solid foods or aspiration risk.\n- **Caregiver education**: Nutritional knowledge, appropriate feeding techniques, and cultural food practices are addressed.\n- **Nutritional support**: If oral intake remains insufficient despite intervention, tube feeding is considered."
  },
  {
    "article_id": 139,
    "article_title": "Head Trauma",
    "section_id": "eeabd6b38cbe4f02bcdd901b33ed850b",
    "section_title": "Bedside Management",
    "variant": "clinical",
    "imperatives": 5,
    "content": "**Primary Survey**\n\n1. **Airway and Breathing**: The airway is secured. Respiratory support is provided if Glasgow Coma Scale is less than 8 or the child is responsive only to pain.\n\n2. **Circulation**: Vital signs are assessed. Blood is obtained for full blood count and group and cross-match. Crystalloid 20 ml/kg is administered and the patient is reassessed. Shock does not occur from isolated head injury beyond infancy.\n\n3. **Disability**: Consciousness level is assessed. Pupil size and reactivity are examined. If unequal pupils or concerns regarding head injury are present, neuroprotection measures are initiated, CT head imaging is arranged, and neurosurgical consultation is obtained.\n\n4. **Exposure and Temperature Control**: All clothing is removed. All parts of the body are examined. Hypothermia is avoided. Analgesia is considered. A gastric tube is placed (not a nasal tube in head injury).\n\n**Secondary Survey**\n\nOnce the child's condition is stabilized, a complete secondary survey is performed to identify all injuries. X-rays of chest and pelvis are considered. Surgical opinion is sought if ruptured liver/spleen, fractured pelvis, or long bone fracture is suspected.\n\n**Special Populations**\n\nIn children with [[209|hemophilia]] and major head trauma, immediate treatment with replacement therapy is initiated to achieve 100% factor activity level. For minor trauma without symptoms or external evidence of injury in mild hemophilia, replacement therapy may not be required; the physician must assess the type of trauma and bleeding history to determine need."
  },
  {
    "article_id": 140,
    "article_title": "Neonatal Fever",
    "section_id": "fb754fde9a8e4b4987a005b5e1cf1dd5",
    "section_title": "In short",
    "variant": "short",
    "imperatives": 1,
    "content": "- Fever is defined as ≥38°C but only ~50% of infected neonates develop fever; hypothermia may be the only sign\n- Neonatal immune defences are immature: decreased neutrophil function, low immunoglobulin G and complement, underdeveloped lymph node germinal centres\n- Common pathogens include Group B streptococcus, *E. coli*, *Listeria monocytogenes*, *Enterococcus*, *Staphylococcus aureus*, and HSV\n- Presentation is often nonspecific: irritability, lethargy, poor feeding, rash, jaundice, respiratory symptoms, hepatomegaly, or abdominal distention\n- Symptoms may begin on day 1 of life; severe disease typically emerges within the first 2 weeks\n- Physical examination alone cannot reliably predict serious infection\n- All febrile neonates require complete blood count, blood culture, urine culture, and CSF study; chest X-ray if respiratory cause suspected\n- All febrile neonates must be hospitalised and given intravenous antibiotics regardless of clinical appearance or initial lab results\n- Ceftriaxone is avoided due to bilirubin displacement risk\n- Non-infectious causes (over-bundling, [[99|dehydration]] fever) may present with fever in a well-appearing infant"
  },
  {
    "article_id": 140,
    "article_title": "Neonatal Fever",
    "section_id": "70f71ff6ae3a4c72a65e05070662b1ad",
    "section_title": "Management of febrile neonates (0–28 days)",
    "variant": "clinical",
    "imperatives": 8,
    "content": "**Initial assessment:**\n- Detailed history is obtained, including maternal illness, delivery circumstances, and symptom onset\n- Thorough physical examination is performed, repeated if necessary\n- Danger signs are assessed for: abnormal temperature (hypothermia <36°C or fever ≥38°C), tachypnea >60 breaths/min, [[151|respiratory distress]], apnea, tachycardia >180 beats/min, delayed capillary refill >3 seconds, weak or bounding pulses, abnormal abdominal or neurologic findings\n\n**Investigations (all febrile neonates):**\n- Complete blood count\n- Blood culture\n- Urine culture (via catheterisation or suprapubic aspiration)\n- Cerebrospinal fluid study and culture (lumbar puncture)\n- Chest X-ray if respiratory cause suspected\n\n**Empiric antibiotic therapy:**\nIntravenous antibiotics are started immediately after investigations are sent, without awaiting results.\n\n*Neonates 0–7 days of age:*\n- Ampicillin PLUS Gentamicin\n- Some experts add a third or fourth generation cephalosporin if cerebrospinal fluid Gram stain shows gram-negative organisms\n\n*Neonates 8–28 days of age:*\n- Ampicillin PLUS Cefotaxime (or Ceftazidime or Cefepime if Cefotaxime unavailable)\n- Some experts add an aminoglycoside if cerebrospinal fluid Gram stain shows gram-negative organisms\n\n**Important considerations:**\n- Ceftriaxone is avoided (risk of bilirubin displacement and hyperbilirubinaemia)\n- All febrile neonates are admitted regardless of clinical appearance or initial laboratory results\n- Toxic-appearing neonates are treated aggressively\n- For well-appearing febrile neonates with suspected non-infectious cause (over-bundling), observation for [[226|sepsis]] signs is maintained\n- Specific antibiotic choice and duration are guided by culture results and organism susceptibility once available\n- Some experts recommend repeat lumbar puncture to document cerebrospinal fluid sterility\n- Empiric acyclovir with surface, blood, and cerebrospinal fluid HSV sampling is considered for infants at increased risk\n\n**Follow-up:**\n- Parents are counselled on danger signs requiring immediate return\n- Outpatient follow-up is arranged for infants with no identified focus on initial evaluation"
  },
  {
    "article_id": 141,
    "article_title": "Pediatric Dermatology",
    "section_id": "ccc88964091f4f0d8a0a37cf5d761d04",
    "section_title": "Clinical Assessment",
    "variant": "clinical",
    "imperatives": 2,
    "content": "**History and Examination**\n\nEvaluation begins with a systematic history addressing the onset, distribution, and progression of the rash. Associated symptoms, triggers, and any treatments already attempted are documented. The lesions are examined carefully, noting their morphology, distribution pattern, and any secondary changes.\n\n**Lesion Morphology**\n\nLesions are classified by type (papules, vesicles, pustules, plaques, erythema), as this guides the differential diagnosis. Papulosquamous and vesiculopustular eruptions are the most common presentations in children.\n\n**Special Considerations**\n\nFor pigmented lesions, particularly those involving the nail unit, size, color uniformity, and any changes over time are documented. Specialist evaluation is sought if there is diagnostic uncertainty or concerning features.\n\nFor neonatal presentations, the age of onset and associated systemic symptoms are considered. Diaper dermatitis, seborrheic dermatitis, and vascular lesions require different management approaches.\n\n**Documentation**\n\nFindings are recorded with clear description of morphology and distribution. This documentation supports accurate diagnosis and guides appropriate management or referral."
  },
  {
    "article_id": 142,
    "article_title": "Altered Mental Status",
    "section_id": "5d9e2c5dcada45e89f1115282431ab21",
    "section_title": "Bedside Assessment and Management",
    "variant": "clinical",
    "imperatives": 5,
    "content": "**Initial Assessment**\n\nEvaluation begins with rapid assessment of consciousness level and vital signs. Arousal is assessed by observing spontaneous activity and response to stimulation. Awareness is evaluated by testing orientation to person, place, and time where age-appropriate.\n\n**Focused Neurologic Examination**\n\nPupils are examined for size, symmetry, and reactivity. Extraocular movements are tested for impairment. Motor function is assessed for focal weakness or asymmetry. Reflexes are checked for asymmetry. Meningeal signs (nuchal rigidity, Kernig sign) are sought. Abnormal posturing, seizure activity, or involuntary movements are observed for.\n\n**Red Flag Findings Suggesting Structural Pathology**\n\n- Asymmetric or dilated pupils\n- Cranial nerve VI palsy\n- Focal weakness or asymmetrical reflexes\n- Abnormal posturing\n- Cushing triad (bradycardia, [[92|hypertension]], Cheyne-Stokes breathing)\n\n**Red Flag Findings Suggesting Infection**\n\n- Fever with headache, photophobia, and nuchal rigidity\n- Poor perfusion with fever ([[226|sepsis]])\n\n**Red Flag Findings Suggesting Trauma**\n\n- History of head injury\n- Scalp or skull hematoma or ecchymoses\n- Retinal hemorrhages (concerning for nonaccidental trauma)\n\n**Next Steps**\n\nBased on clinical presentation, appropriate investigations are obtained: laboratory tests for metabolic causes (uremia, sepsis), lumbar puncture for CNS infection, neuroimaging (CT or MRI) for structural lesions, and EEG if seizure is suspected. Management is directed at the underlying cause once identified."
  },
  {
    "article_id": 143,
    "article_title": "Anaphylaxis",
    "section_id": "77853f6f9f0147cea2e1892186c9242a",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 2,
    "content": "**Immediate Actions**\n\n1. Airway, breathing, and circulation are assessed\n2. Emergency help is called for (911/EMS in community settings; resuscitation team in healthcare settings)\n3. The patient is positioned on their back or in a position of comfort if [[151|respiratory distress]] or vomiting is present\n4. The lower extremities are elevated\n5. Standing, walking, or running is not allowed\n\n**Medication**\n\n**Epinephrine (adrenaline)** is the primary initial treatment:\n- Route: Intramuscular injection in the mid-outer aspect of the thigh\n- Administration: An epinephrine auto-injector (EA) is used\n- Second dose: May be given 5 to 15 minutes after the first injection if needed\n\n**Additional Supportive Care**\n\n- Supplemental oxygen\n- Intravenous fluids\n- Corticosteroids\n- H1 antihistamines\n- H2 antihistamines\n\n**Transport**\n\nThe patient is transported to an emergency department, preferably by EMS vehicle, for further assessment and monitoring. Continued observation is essential because biphasic reactions can occur."
  },
  {
    "article_id": 144,
    "article_title": "Feeding Intolerance",
    "section_id": "18d9ae561259460889e834a9a8cfd36e",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Step 1: Initial Recognition and Stabilization**\n\nFeeding intolerance is identified by the presence of increased gastric residual volume, bilious or blood-stained stomach contents, abdominal distension, vomiting, diarrhea, bloating, or signs of microaspiration.\n\n**Step 2: Withhold and Observe**\n\nEnteral nutrition is withheld for 6–12 hours. Close observation is maintained for worrying symptoms (signs of necrotizing enterocolitis, sepsis, or acute deterioration).\n\n**Step 3: Decision Point Based on Clinical Course**\n\n*If no worrying symptoms and intolerance resolves:*\n- Enteral feeding is restarted\n- Step 4 follows\n\n*If worrying symptoms develop or clinical condition worsens:*\n- Enteral nutrition is withdrawn\n- Abdominal radiography and ultrasound are performed\n- Imaging is repeated every 6 hours\n- Observation continues for at least 48–72 hours\n- Once resolved, Step 5 follows\n\n**Step 4: Minimal Enteral Feeding (if intolerance persists without worrying symptoms)**\n\n- Enteral feeding is restarted at 50% of the previous volume\n- Observation continues for at least 24 hours\n- If intolerance persists or reappears without worrying symptoms, Step 5 follows\n- If no intolerance, feeding advances\n\n**Step 5: Feeding Regimen Modifications**\n\nOne or more of the following are adjusted:\n- **Schedule:** Bolus feeding is changed to continuous feeding\n- **Rate:** The infusion rate is decreased\n- **Concentration:** The formula is concentrated to decrease volume\n- **Formula:** Changing to a different formula is considered\n- **Fluid intake:** Adequate hydration is ensured\n\n**Step 6: Medical Management**\n\nConsidered:\n- Acid-suppressing therapy for [[245|gastroesophageal reflux]]\n- Prokinetic agents to enhance gastric motility\n\n**Step 7: Advancement After Resolution**\n\nOnce feeding intolerance resolves, enteral nutrition is increased by 20–30 ml/kg/day.\n\n**Ongoing Monitoring**\n\nA multidisciplinary team (physician and registered dietitian nutritionist):\n- Monitors enteral feeding tolerance at each assessment\n- Tracks growth trends\n- Reviews relevant laboratory values\n- If the child is also eating by mouth, evaluates the combination of tube and oral feedings to ensure adequate nutrient intake"
  },
  {
    "article_id": 145,
    "article_title": "Functional Abdominal Pain",
    "section_id": "eee00b22d506493f8803e627d930d022",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 5,
    "content": "**Initial Assessment**\n\n1. A detailed history is taken and a complete physical examination is performed\n2. Red flag symptoms and signs are identified: unintentional weight loss, blood in stools, persistent right upper or lower abdominal pain, persistent vomiting, dysphagia, odynophagia, arthritis, family history of [[254|inflammatory bowel disease]], or nocturnal diarrhea\n\n**If Red Flags Are Present**\n\nIf symptoms are consistent with [[193|acute abdomen]]:\n- The patient is kept nothing by mouth\n- Surgical consultation is requested\n- Antibiotics are started:\n  - **Piperacillin/tazobactam**: 350 mg/kg/day divided into doses every 6 hours (maximum 12 g/day), OR\n  - **IV meropenem**: 20 mg/kg every 8 hours (maximum 6 g/day), OR\n  - **Cefoxitin**: 30 mg/kg every 6 hours (maximum 12 g/day), OR\n  - **Cefotetan**: 30 mg/kg every 12 hours (maximum 12 g/day)\n- Directed laboratory studies and imaging are arranged as indicated\n\n**If No Red Flags Are Present**\n\n1. Limited screening laboratory studies are performed\n2. Parents are reassured that no organic basis for pain exists\n3. Placebo medications are not prescribed\n4. Behavioral and psychological approaches are counselled:\n   - Relaxation techniques (deep breathing exercises)\n   - Distraction strategies (conversation, television, games)\n   - Identification and management of psychosocial stressors\n5. Symptoms typically improve on weekends and vacations\n6. Most children improve with coping strategies alone\n7. Referral and consultation are considered as indicated by clinical context"
  },
  {
    "article_id": 146,
    "article_title": "Hypertrophic Cardiomyopathy",
    "section_id": "7d2a3015193845d2bd2d4abd39b385dd",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 10,
    "content": "**Initial Assessment**\n- ECG and echocardiography are obtained to confirm diagnosis and assess for LVOT obstruction\n- Exercise stress testing is performed as part of risk stratification\n- [[334|Syncope]] (especially exertional) is evaluated for as a major risk factor for sudden cardiac death\n- Family history is obtained and genetic counseling is arranged\n\n**Pharmacological Management**\n- Negative inotropic agents are initiated:\n  - Beta-blockers (first-line)\n  - Calcium channel blockers (alternative)\n- Adequate hydration is maintained; HCM is preload dependent and patients may benefit from higher rates of fluid administration\n- Positive inotropes, medications that increase heart rate, and afterload-reducing agents are avoided\n\n**Activity and Lifestyle**\n- Moderate restriction of physical activity is implemented\n- Competitive athletics are counselled against\n- Genetic counseling is provided and family member evaluation is recommended\n\n**Risk Stratification and Intervention**\n- Patients at increased risk for sudden cardiac death are identified\n- Implantable cardioverter-defibrillator placement is considered in high-risk patients\n- Symptomatic patients with subaortic obstruction are referred for possible myectomy\n\n**Follow-up**\n- Ongoing [[121|pediatric cardiology]] follow-up is arranged\n- Risk stratification is reassessed periodically"
  },
  {
    "article_id": 147,
    "article_title": "Meningitis",
    "section_id": "6acd91b043c140a3bcb4ad8fcab2e4db",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Immediate Actions**\n\n- Any febrile child with a purpuric rash receives intramuscular benzylpenicillin immediately and is transferred urgently to hospital without waiting for confirmatory tests\n- Imaging (CT or MRI) is obtained before lumbar puncture to exclude hydrocephalus or mass lesion\n- Lumbar puncture is performed and cerebrospinal fluid is sent for Gram stain, culture, and analysis\n- In patients with ventriculoperitoneal shunts, cerebrospinal fluid is obtained via shunt tap if present\n\n**Antibiotic Therapy**\n\nFor shunt-related meningitis in patients who are seriously ill, vancomycin and a third-generation cephalosporin (cefotaxime or ceftriaxone) are initiated to cover Staph aureus, coagulase-negative staphylococci (including methicillin-resistant strains), and gram-negative rods. In less seriously ill patients without shunt infection, therapy may be postponed while awaiting Gram stain and culture results.\n\n**Antibiotic Susceptibility Considerations**\n\nFor *Streptococcus pneumoniae* meningitis, penicillin and cephalosporin susceptibility are interpreted using meningitis-specific breakpoints:\n- Penicillin (intravenous): susceptible ≤0.06 mcg/mL; resistant ≥0.12 mcg/mL (no intermediate category)\n- Cefotaxime or ceftriaxone (intravenous): susceptible ≤0.5 mcg/mL; intermediate 1 mcg/mL; resistant ≥2 mcg/mL\n\n**Supportive Care**\n\n- General and supportive measures are provided as indicated\n- Monitoring occurs for syndrome of inappropriate antidiuretic hormone, which may accompany meningitis\n- Increased intracranial pressure from cerebral edema or hydrocephalus is managed"
  },
  {
    "article_id": 148,
    "article_title": "Menorrhagia",
    "section_id": "8e247709f6b34a1cb7571821ff9b75f0",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 8,
    "content": "**Initial Assessment**\n\n1. A detailed menstrual history is obtained, including age at menarche, cycle regularity, and duration of amenorrhea\n2. Pubertal development is assessed (breast and pubic hair staging)\n3. Confidential sexual history is taken and pregnancy is screened for\n4. Medications, hormonal contraceptive use, exercise intensity, dietary habits, stress, and systemic illness are inquired about\n\n**First-Line Investigations**\n\nThe following tests are ordered:\n- Thyroid-stimulating hormone (TSH)\n- Prolactin\n- Follicle-stimulating hormone (FSH)\n- Human chorionic gonadotropin (HCG)\n- Pelvic ultrasound (for [[394|primary amenorrhea]])\n\n**Interpretation and Next Steps**\n\n**If FSH is low or normal:**\n- Suggests hypothalamic or pituitary dysfunction\n- Eating disorders, excessive exercise, stress, systemic illness, and constitutional delay are evaluated for\n- Screening for celiac disease and other autoimmune disorders is considered\n\n**If FSH is elevated:**\n- Suggests ovarian insufficiency\n- FSH testing is repeated\n- Celiac and other autoimmune disorders are evaluated for\n- Karyotype analysis is considered\n- Pelvic and adrenal imaging are ordered\n- Specialist referral is arranged\n\n**Bone Health Assessment**\n\nAfter 6 months or more of amenorrhea, bone densitometry is performed to assess for low bone density, particularly in patients with functional hypothalamic amenorrhea or relative energy deficiency in sport.\n\n**Management of Hormonal Contraceptive-Related Amenorrhea**\n\nAmenorrhea occurring during hormonal contraceptive use does not require immediate investigation. However, if amenorrhea persists for 12 months after the last injection of medroxyprogesterone or for 6 months after discontinuation of birth control pills, rings, or patches, standard evaluation as outlined above is undertaken."
  },
  {
    "article_id": 149,
    "article_title": "Nutritional Deficiency",
    "section_id": "1439818490bf46878149478d33e1bc0c",
    "section_title": "Management of Niacin Deficiency",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Diagnosis and confirmation:**\n- 24-hour urine niacin measurement is obtained\n- RBC NAD/NADP number is measured\n- Detailed dietary history is taken and risk factors are assessed\n\n**Treatment:**\n- Niacin: 50–100 mg per dose, orally, three times daily for several weeks\n- Dietary sources are ensured to be adequate: beef, liver, fish, pork, wheat flour, eggs\n- Underlying causes are addressed (e.g., medication review for isoniazid, anticonvulsants, antidepressants, 5-fluorouracil, 6-mercaptopurine, chloramphenicol, sulfonamides)\n\n**Monitoring:**\n- Resolution of gastrointestinal symptoms (diarrhea, anorexia) is assessed\n- Skin changes (dermatitis, sun-exposed areas) are monitored\n- Neurological improvement (dementia, glossitis, angular stomatitis) is evaluated"
  },
  {
    "article_id": 151,
    "article_title": "Respiratory Distress",
    "section_id": "0b3177a27aa74b4f89991b6cf3b55348",
    "section_title": "Bedside Management",
    "variant": "clinical",
    "imperatives": 2,
    "content": "**Initial Assessment and Stabilisation**\n\n1. **Airway, Breathing, Circulation (ABC)** — This is the first priority\n   - Airway patency is assessed urgently\n   - Breathing adequacy is determined\n   - Circulation is evaluated\n\n2. **Positioning and Airway Clearance**\n   - The child is positioned appropriately\n   - Oronasal suctioning is performed if needed to clear secretions\n\n3. **Oxygen Delivery**\n   - Supplementary oxygen is provided as needed\n   - Oxygen hood or nasal prongs are used\n   - Oxygen saturation (SpO₂) is monitored\n\n4. **Intubation**\n   - Intubation is performed if airway patency cannot be maintained\n   - Note: Children have significant anatomical variation with age—shorter trachea, smaller tracheal diameter, and technically difficult intubation; risk of right mainstem intubation, tube dislodgement, or oesophageal intubation\n\n**Supportive Measures**\n\n5. **Temperature Management**\n   - Normal temperature is maintained\n   - Hypothermia or hyperthermia is corrected\n\n6. **Fluid and Metabolic Support**\n   - Intravenous fluid boluses are administered\n   - Hypoglycaemia is corrected\n\n7. **Respiratory Support**\n   - CPAP (continuous positive airway pressure) is considered\n   - Nebulisation with bronchodilators is given as indicated\n   - Positive pressure ventilation is used for severe cases\n\n8. **Specific Therapy for RDS**\n   - Surfactant replacement therapy is given for confirmed RDS\n   - Positive pressure ventilation is used for severe cases\n\n9. **Drainage**\n   - Intercostal tube drainage is placed if air or fluid is present\n\n**Concurrent Assessment**\n\n- Severity and type of respiratory problem are determined simultaneously\n- Laboratory studies (CBC, arterial blood gas, serum electrolytes, blood culture) are obtained as indicated\n- Chest radiography is performed\n- Detailed evaluation is pursued to determine underlying aetiology"
  },
  {
    "article_id": 152,
    "article_title": "Tuberculosis",
    "section_id": "44625598c99f458cafc30d6bd46bda5e",
    "section_title": "Management of Congenital Tuberculosis",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Immediate Evaluation**\n- Tuberculin skin test\n- Interferon-gamma release assay\n- Chest radiography\n- Lumbar puncture\n- Appropriate cultures\n- Placental histology for granulomata and acid-fast bacilli\n- Placental culture for *M. tuberculosis* complex\n\n**Treatment (initiated promptly regardless of TST/IGRA results)**\n- Rifampin, once daily\n- Isoniazid, once daily\n- Pyrazinamide, once daily\n- Either ethambutol (RIPE regimen) OR aminoglycoside (streptomycin, kanamycin, or amikacin) OR capreomycin, once daily\n\n**If Meningitis Confirmed**\n- Corticosteroids are added\n\n**Maternal Evaluation**\n- Pulmonary and extrapulmonary tuberculosis, including genitourinary disease, are assessed for\n- HIV testing is performed (essential)\n- Drug susceptibility testing is performed on maternal isolate"
  },
  {
    "article_id": 152,
    "article_title": "Tuberculosis",
    "section_id": "8908f4ca902847d2a4ef09f9844eb776",
    "section_title": "Management of Tuberculosis Meningitis",
    "variant": "clinical",
    "imperatives": 4,
    "content": "**Initial Assessment**\n- Lumbar puncture is performed in all children <12 months with suspected TB disease; in children ≥12 months only if neurological signs or symptoms are present\n- Chest radiography and TST/IGRA are obtained\n- Cerebrospinal fluid is sent for culture and acid-fast bacilli examination\n\n**Drug-Susceptible *M. tuberculosis* Meningitis**\n\n*Intensive phase (2 months):*\n- Isoniazid, once daily\n- Rifampin, once daily\n- Pyrazinamide, once daily\n- Aminoglycoside OR ethionamide, once daily\n\n*Continuation phase (7–10 months):*\n- Isoniazid, once daily or twice weekly\n- Rifampin, once daily or twice weekly\n\n**Total duration:** 9–12 months\n\n**Drug-Susceptible *M. bovis* Meningitis**\n- At least 12 months of therapy without pyrazinamide\n\n**Geographic Considerations**\n\n- In areas with common streptomycin resistance, kanamycin, amikacin, or capreomycin is substituted for aminoglycoside\n\n**Adjunctive Therapy**\n\n- Corticosteroids are added if [[147|meningitis]] is confirmed\n\n**Drug Susceptibility Testing**\n\n- Performed on organism recovered from patient or mother"
  },
  {
    "article_id": 155,
    "article_title": "Congenital Infection",
    "section_id": "1afa5f09beb7457e94348d278d843c42",
    "section_title": "Clinical Evaluation and Management",
    "variant": "clinical",
    "imperatives": 6,
    "content": "**Initial Assessment**\n\nWhen congenital infection is suspected, a detailed maternal history is obtained, including primary infection timing, serologic status, and exposure risks. Thorough physical examination is performed, documenting growth parameters, hepatosplenomegaly, rash characteristics, jaundice, and neurologic findings.\n\n**Diagnostic Workup**\n\nFor suspected [[341|toxoplasmosis]]:\n- Newborn and maternal serology are obtained: toxoplasma-specific IgG, IgM, IgA, and IgE\n- Infant blood, cerebrospinal fluid, and amniotic fluid are sent to a reference laboratory for PCR detection of *Toxoplasma gondii*\n- Lumbar puncture is performed\n- Thorough ophthalmologic, auditory, and neurologic evaluation is arranged\n\nFor suspected CMV:\n- Cord blood or infant urine is tested for CMV by PCR or culture\n- CMV-specific serology is obtained if indicated\n\nFor suspected HHV-6:\n- HHV-6A or HHV-6B DNA is detected in cord blood by PCR\n\n**Interpretation of Serologic Results**\n\nCongenital infection is confirmed serologically by:\n- Persistent or increasing IgG antibody levels in infant compared to mother\n- Persistently positive IgG antibodies beyond the first year of life\n- Positive *Toxoplasma*-specific IgM or IgA antibody in infant\n- Persistence of other antibody types also indicates infant infection\n\n**Imaging and Additional Studies**\n\nFor symptomatic congenital CMV, neuroimaging is obtained to assess for periventricular calcifications, cerebral atrophy, and hydrocephalus. Ophthalmologic examination is performed to detect chorioretinitis. Auditory assessment including formal audiometry is arranged."
  },
  {
    "article_id": 156,
    "article_title": "Infantile Hemangioma",
    "section_id": "e9df2fb7b0b34c4685b629d0d52f23d8",
    "section_title": "Management at the Bedside",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Initial Assessment**\n\nThe hemangioma is identified by location (superficial vs. deep), size, and appearance. Superficial lesions are bright red; deep lesions appear bluish. The age of onset and growth pattern are documented. Any functional impairment or complications are assessed for.\n\n**Parental Counselling**\n\nParents are educated about the expected natural history: rapid growth over the first 3–4 months, plateau by 9–12 months, then gradual involution beginning after 12 months and typically completing by 4 years of age. The potential for complications or permanent disfigurement and the rationale for watchful waiting versus intervention are explained.\n\n**Treatment Options**\n\n**Topical therapy:** Topical timolol maleate may be prescribed for thin and/or superficial infantile hemangiomas.\n\n**Surgical and laser therapy:** Considered for selected hemangiomas causing functional impairment or significant disfigurement. Surgery is avoided during the proliferating phase due to high vascularity and risk of blood loss. The optimal timing for surgical resection is between 3 and 4 years of age, when the lesion has stabilized and before the child's long-term memory and self-esteem formation begins.\n\n**Follow-up**\n\nLesions are monitored clinically during the proliferating and involuting phases. Imaging is typically reserved for deeper subcutaneous lesions without typical skin findings or when diagnosis is unclear."
  },
  {
    "article_id": 157,
    "article_title": "Lymphoma",
    "section_id": "fcbb08a0521d4223a33dd7efcd30cd32",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Assessment and Diagnosis**\n\nWorrisome lymphadenopathy features are evaluated for: systemic symptoms (fever, night sweats, weight loss), fixed nontender nodes, and supraclavicular involvement. Lymphoma is considered in patients older than 3 years presenting with intussusception or abdominal symptoms (crampy pain, vomiting, obstruction, bleeding, palpable mass).\n\n**Treatment by Disease Extent**\n\n*Localized disease with complete surgical resection:*\n- Multiagent chemotherapy over 6 weeks\n- COPAD regimen: two cycles of cyclophosphamide, vincristine, prednisone, and doxorubicin\n- Expected 4-year overall survival: 99%\n\n*Advanced disease:*\n- Multiagent chemoimmunotherapy regimen\n- Duration: 4 to 6 months\n- Examples: FAB/LMB 96 protocol therapy or COG ANHL01P1 (which includes rituximab)\n- Treatment phases typically include reduction, induction, intensification, and maintenance therapy\n- 4-year overall survival: 95%\n\n*Gastrointestinal lymphoma:*\n- Combination of surgical resection and chemotherapy\n\n**Risk Stratification**\n\nTreatment intensity and specific protocols are adjusted based on risk stratification, including consideration of bone marrow and central nervous system involvement at presentation."
  },
  {
    "article_id": 158,
    "article_title": "Measles",
    "section_id": "b2faefea3cd4473291ddce2f76c85f33",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 4,
    "content": "**Diagnosis and Confirmation**\n\n- IgM assay is obtained for serologic confirmation\n- PCR or virus isolation from urine, blood, or throat/nasopharyngeal secretions is considered if IgM is unavailable\n\n**Isolation Precautions**\n\n- Standard and airborne precautions are implemented for all hospitalised patients\n- Isolation is maintained from 7 days after exposure through 4–6 days after rash onset\n- For immunocompromised patients: isolation continues throughout the entire illness as viral shedding is prolonged\n- Exposed hospitalised patients: isolation occurs for 5–21 days following exposure\n\n**Supportive Care**\n\n- Fever and symptoms are managed with supportive measures\n- Secondary bacterial infections ([[160|otitis media]], bronchopneumonia, croup, diarrhea) are monitored for, which occur commonly in young children and immunocompromised hosts\n- Complications including encephalitis and haemorrhagic manifestations are assessed for\n\n**Exposure Management**\n\n- Susceptible individuals should avoid contact with infected patients during the infectious period\n- Unvaccinated or inadequately vaccinated close contacts require post-exposure evaluation and vaccination consideration"
  },
  {
    "article_id": 159,
    "article_title": "Neonatal Seizures",
    "section_id": "f0793185ec164aeeb43a3fbb645f1bc0",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 1,
    "content": "**Initial Assessment and Stabilization**\n\nWhen a neonate presents with suspected seizure activity, immediate evaluation is essential. Adequate oxygenation and ventilation are ensured. True seizures are distinguished from neonatal mimics such as jitteriness or benign sleep myoclonus (which occurs only during sleep and resolves on awakening).\n\n**Identification and Treatment of Reversible Causes**\n\nBefore antiseizure medication is started, electrolyte abnormalities and hypoglycemia are identified and treated urgently, as these are rapidly reversible causes:\n\n- **[[321|Hypoglycemia]]**: All seizing infants are treated with glucose. Thresholds vary by postnatal age: <25–40 mg/dL in first 4 hours, <35–45 mg/dL from 4–24 hours, <45 mg/dL from 24–48 hours, <60 mg/dL thereafter\n- **[[368|Hypocalcemia]]**: Defined as calcium <8 mg/dL in infants >1,500 g birthweight; <7 mg/dL in very low birthweight infants\n- **Hypomagnesemia**: Assessed and corrected as indicated\n\n**Pharmacological Management**\n\nFor infrequent or transient seizures:\n- **Diazepam**: 0.1–0.5 mg/kg IV\n- **Lorazepam**: 0.1 mg/kg IV\n\nIf seizures do not stop, occur more frequently, or become more severe, therapy is escalated. Respiratory support (ventilator in ICU setting) must be available whenever IV benzodiazepines or phenobarbital are administered.\n\nFor ongoing or repeated seizures requiring sustained control, antiseizure medications are used, though their efficacy in suppressing seizures is considerably poorer in neonates than in older children.\n\nFor refractory seizures, general anesthesia with endotracheal intubation is required. Agents used in this setting include continuous infusion of midazolam, propofol, ketamine, or pentobarbital.\n\n**Diagnostic Workup**\n\nConcurrently with seizure management, investigation of underlying cause is pursued based on clinical presentation and timing of seizure onset. This may include neuroimaging, cerebrospinal fluid analysis, metabolic screening, and infectious disease evaluation as clinically indicated."
  },
  {
    "article_id": 160,
    "article_title": "Otitis Media",
    "section_id": "764e5ce1df9642f78771a78507b4116c",
    "section_title": "Management",
    "variant": "clinical",
    "imperatives": 3,
    "content": "**Diagnosis at the bedside**\n\nThe diagnosis is confirmed using pneumatic otoscopy. Findings sought include:\n- Moderate to severe bulging of the tympanic membrane, OR\n- New-onset otorrhea not due to acute [[316|otitis externa]]\n\nSupporting features include rapid symptom onset, fever, otalgia or ear tugging, and recent upper respiratory tract infection history.\n\n**First-line treatment**\n\nAmoxicillin (oral): **80–90 mg/kg/day** for at least 7 days\n\nAlternative: Ceftriaxone (single dose) in certain cases\n\n**Second-line agents** (if first-line unsuitable):\n- Coamoxiclav\n- Cefaclor\n- Cefuroxime\n- Newer-generation cephalosporins\n- Macrolides (for penicillin and/or cephalosporin allergy)\n\n**Follow-up**\n\n- Otoscopic examination is repeated at 3–4 days\n- Otoscopic examination is repeated at 3 weeks\n\n**Not prescribed**\n\n- Oral or topical decongestants (not necessary)\n- Antihistamines (ineffective and may precipitate sinus infection)\n- Antibiotics for [[258|otitis media with effusion]]\n\n**Special note**\n\nTympanocentesis is not performed routinely; treatment is empirical. Clinical features cannot reliably predict causative organism in individual children."
  }
]